Drotrecogin alfa (activated) approved for treatment of severe sepsis.
Drotrecogin alfa (activated) is a recombinant form of human activated protein C that has been shown to reduce mortality in severely septic patients with a high risk of death. Given the complexity of the inclusion and exclusion criteria, the stability and unique duration of infusion, and the cost of treatment, therapy with this agent should be carefully considered to ensure its appropriate use.
Poe
Kevin
K
St Joseph's Hospital, Lexington, KY, USA.
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D011486:Protein C / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011493:Protein Kinase C / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; D011493:Protein Kinase C; C421124:drotrecogin alfa activated